Inventor
Nathanael S. Gray
Inventor
Boston, MA, US
Overview
Patents· 110 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds35%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes18%
Y02ATechnologies for adaptation to climate change4%
C07CAcyclic or carbocyclic compounds4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07HSugars1%
C07KPeptides1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
C04BLime, magnesia0%
PatentTitleYear
10,875,844Salicylate inhibitors of MELK and methods of use202010,870,651Inhibitors of cyclin-dependent kinase 7 (CDK7)202010,870,636Pyrimidines as EGFR inhibitors and methods of treating disorders202010,865,204Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use202010,865,205Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use202010,842,878Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use202010,844,077Thiazolyl-containing compounds for treating proliferative diseases202010,836,722Inhibitors of EGFR and methods of use thereof202010,793,571Uses of diazepane derivatives202010,787,436Inhibitors of cyclin-dependent kinase 7 (CDK7)202010,787,455Small molecule myristate inhibitors of BCR-ABL and methods of use202010,787,461Pyrimido-diazepinone compounds and methods of treating disorders2020RE048175Hydrophobically tagged small molecules as inducers of protein degradation202010,723,753Ras inhibitors and uses thereof202010,711,036MALT1 inhibitors and uses thereof202010,710,978STK4 inhibitors for treatment of hematologic malignancies202010,702,527Combination therapy of transcription inhibitors and kinase inhibitors202010,695,3464,6-pyrimidinylene derivatives and uses thereof202010,689,366Compounds for MALT1 degredation202010,633,348Methods to treat lymphoplasmacytic lymphoma202010,597,387Methods to treat lymphoplasmacytic lymphoma202010,570,154Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders202010,550,112Pyrimidines as EGFR inhibitors and methods of treating disorders202010,550,121Inhibitors of cyclin-dependent kinases202010,544,138Tricyclic kinase inhibitors of MELK and methods of use202010,532,103Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use202010,525,060HCK as a therapeutic target in MYD88 mutated diseases202010,508,082Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK201910,464,949Thiazolyl-containing compounds for treating proliferative diseases201910,457,691Macrocyclic kinase inhibitors and uses thereof201910,457,692Pyrimido-diazepinone compounds and methods of treating disorders201910,450,310Bifunctional molecules for degradation of EGFR and methods of use201910,450,281Compounds and methods for treating cancer201910,385,019Inhibitors of EGFR and methods of use thereof201910,342,798Fused bicyclic pyrimidine derivatives and uses thereof201910,316,002Kinase inhibitors for the treatment of disease201910,287,268Imidazolyl kinase inhibitors and uses thereof201910,265,321Uses of salt-inducible kinase (SIK) inhibitors201910,266,517Pyrimidines as EGFR inhibitors and methods of treating disorders201910,233,157SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder201910,189,861Pyrimido-diazepinone compounds and methods of treating disorders201910,150,742Substituted heterocyclic compounds for treating or preventing viral infections201810,144,730Inhibitors of c-Jun-201810,112,927Inhibitors of cyclin-dependent kinase 7 (CDK7)201810,112,957Thiazolyl-containing compounds for treating proliferative diseases201810,081,639Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders201810,047,070Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)201810,017,477Janus kinase inhibitors and uses thereof201810,000,483Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof20189,908,884'EGFR inhibitors and methods of treating disorders'20189,908,872'Methods to treat lymphoplasmacytic lymphoma'20189,879,028'Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith'20189,879,003'Host targeted inhibitors of dengue virus and other viruses'20189,862,688'Hydrophobically tagged janus kinase inhibitors and uses thereof'20189,856,223'Methods to treat lymphoplasmacytic lymphoma'20189,783,504'Kinase inhibitors for the treatment of disease'20179,758,522'Hydrophobically tagged small molecules as inducers of protein degradation'20179,725,425'Compounds and methods for treating cancer'20179,701,683'Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders'20179,695,172'Diazepane derivatives and uses thereof'20179,676,792'Pyrimido-diazepinone compounds and methods of treating disorders'20179,670,214'Small molecule myristate inhibitors of Bcr-abl and methods of use'20179,670,165'SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder'20179,505,784'Fused 2-aminothiazole compounds'20169,464,091'Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders'20169,382,239'Inhibitors of c-Jun-N-terminal kinase (JNK)'20169,358,231'Type II RAF kinase inhibitors'20169,266,890'Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders'20169,180,127'Type II Raf kinase inhibitors'20158,987,275'Indazole compounds and their uses'20158,921,336'Small molecule myristate inhibitors of BCR-ABL and methods of use'20148,889,706'Soluble mTOR complexes and modulators thereof'20148,765,747'Fused 2-aminothiazole compounds'20148,592,433'Compounds and compositions as protein kinase inhibitors'20138,552,002'Compounds and compositions as protein kinase inhibitors'20138,394,818'Soluble mTOR complexes and modulators thereof'20138,183,248'Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors'20128,101,608'Compounds and compositions as protein kinase inhibitors'20127,968,557'Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors'20117,939,519'Immunosuppresant compounds and compositions'20117,893,074'2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders'20117,868,018'Compounds and compositions as protein kinase inhibitors'20117,750,021'Immunosuppressant compounds and compositions'20107,745,437'Compounds and compositions as protein kinase inhibitors'20107,718,704'Immunosuppressant compounds and compositions'20107,713,958'Compounds and compositions as protein kinase inhibitors'20107,642,255'Compounds and compositions as protein kinase inhibitors'20107,589,101'Compounds and compositions as protein kinase inhibitors'20097,572,811'Immunosuppressant compounds and compositions'20097,569,593'Compounds and compositions as protein kinase inhibitors'20097,462,629'Immunosuppressant compounds and compositions'20087,449,582'Compounds and compositions as protein kinase inhibitors'20087,423,038'Compounds and compositions as protein kinase inhibitors'20087,423,031'Compounds and compositions as protein kinase inhibitors'20087,417,065'Immunosuppressant compounds and compositions'20087,371,750'Compounds and compositions as protein kinase inhibitors'20087,338,957'Compounds and compositions as protein kinase inhibitors'20087,273,864'Compositions and methods for inducing osteogenesis'20077,256,206'Bicyclic compounds and compositions'20077,253,166'6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells'20077,189,729'Methods and compositions as protein kinase inhibitors'20077,176,312'Kinase inhibitor scaffolds and methods for their preparation'20077,169,817'Bis-aromatic alkanols'20077,151,096'Cyclic compounds and compositions as protein kinase inhibitors'20067,060,697'Immunosuppressant compounds and compositions'20066,949,644'Methods for the synthesis of substituted purines'20056,803,371'Purine inhibitors of protein kinases, G proteins and polymerases'20046,617,331'Purine inhibitors of protein kinases, G proteins and polymerases'20036,573,044'Methods of using chemical libraries to search for new kinase inhibitors'20036,255,485'Purine inhibitors of protein kinases, G proteins and polymerases'2001Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2001–2004Based in Berkeley, CA, US· patent location history
2005–2020Patents assigned to SCRIPPS RESEARCH INST (7)· patent assignee history
2005–2011Based in San Diego, CA, US· patent location history
2006–2013Patents assigned to IRM LLC (25)· patent assignee history
2007Based in La Jolla, CA, US· patent location history
2008–2020Based in Boston, MA, US· patent location history
2012–2018Patents assigned to GRAY NATHANAEL S (6)· patent assignee history
2013–2020Patents assigned to DANA FARBER CANCER INST INC (72)· patent assignee history
2014–2017Patents assigned to DENG XIANMING (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| DANA FARBER CANCER INST INC | 72 | 2013–2020 |
| IRM LLC | 25 | 2006–2013 |
| SCRIPPS RESEARCH INST | 7 | 2005–2020 |
| GRAY NATHANAEL Sself | 6 | 2012–2018 |
| DENG XIANMING | 5 | 2014–2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| Boston, Massachusetts, US | 88 | 2008–2020 |
| San Diego, California, US | 17 | 2005–2011 |
| Berkeley, California, US | 4 | 2001–2004 |
| La Jolla, California, US | 1 | 2007 |